Icatibant: HOE 140, JE 049, JE049

Drugs in R and D

Volumn 5, Issue 6, 2004, Pages 343-348

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR ANTAGONIST; ICATIBANT; ORPHAN DRUG; PLACEBO;

AIRWAY OBSTRUCTION; ANGIONEUROTIC EDEMA; ARTICLE; ASCITES; BURN; CANADA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; EUROPE; FOOD AND DRUG ADMINISTRATION; GUINEA PIG; HEART VENTRICLE FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; LIVER DISEASE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMATIC REVIEW; TRACHEA; TREATMENT OUTCOME; UNITED STATES; VASCULAR DISEASE;

ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARRHYTHMIA; BRADYKININ; CLINICAL TRIALS; DRUG APPROVAL; HUMANS; LIVER DISEASES; LUNG DISEASES, OBSTRUCTIVE; RECEPTOR, BRADYKININ B2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 10244240479     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200405060-00006     Document Type: Article

References (26)

1. Profiles of participating companies. BIO 2004: Annual International Convention. Business Forum: 6 Jun 2004
2. Jerini AG. Jerini Concludes its Icatibant Phase II Study in Hereditary Angioedema with Positive Results. Media Release: 26 Aug 2004. Available from URL: http://www.jerini.com
3. Jerini AG. Jerini Initiates Pivotal Registration Study for Icatibant in Hereditary Angioedema. Media Release: 8 Sep 2004. Available from URL: http://wwwjerini.com
4. Jerini AG. Jerini Receives FDA Fast Track Designation for Icatibant in Hereditary Angioedema. Media Release: 22 Jul 2004. Available from URL: http://www.jerini.com
5. Jerini, Jerini Has Been Granted Orphan Drug Designation by U.S. FDA for Icatibant, JE049, to Treat Patients with Angioedema. Media Release: 18 Nov 2003. Available from URL: http://www.jerini.com
6. Proud D. Clinical application of kinin antagonists. Canadian Journal of Physiology and Pharmacology 72 (Suppl. 2): 19, 1994
7. Jerini Jerini Announces Positive Results in a Subcutaneous Bioavailability Study for Icatibant. Media Release: 14 Apr 2004. Available from URL: http://www.jerini.com
8. Wirth KJ, Gehring D, Schölkens BA. Effect of Hoe 140 on bradykinin-induced bronchoconstriction in anesthetized guinea pigs. American Review of Respiratory Disease 148: 702-706, Sep 1993
9. Wirth KJ, Gehring D, Schölkens BA. Effect of HOE 140 on bradykinin-induced bronchoconstriction in anaesthetised guinea pigs. Naunyn-Schmiedeberg's Archives of Pharmacology 344 (Suppl. 2): R141, 1991
10. Jerini. Jerini's Bradykinin Antagonist Icatibant Shows Promise in Treatment of Refractory Ascites in Liver Cirrhosis in a Phase II Study. Media Release: 2 Dec 2003. Available from URL: http://www.jerini.com
11. Sun W, Wainwright CL. The potential antiarrhythmic effects of exogenous and endogenous bradykinin in the ischaemic rat heart in vivo Coronary Artery Disease 5: 541-550, Jun 1994
12. Gaudron P, Hu K, Zdrojewski T, et al. AT1-receptor blocker versus angiotensin converting enzyme inhibitor in acute myocardial infarction? Role of dosage and bradykinin on remodelling, hemodynamics and mortality in the rat model. Journal of the American College of Cardiology 31 (Suppl. 2A): 311, Feb 1998
13. Proud D, Reynolds CJ, Broomfield J. Bradykinin effects in guinea pig tracheal epithelial cells are mediated through a β2 kinin receptor and can be inhibited by the selective antagonist Hoe 140. Journal of Pharmacology and Experimental Therapeutics 264: 1124-1131, Mar 1993
14. Hock FJ, Wirth K, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. British Journal of Pharmacology 102: 769-773, Mar 1991
15. Rhaleb N-E, Rouissi N, Jukic D. Pharmacological characterization of a new highly potent β2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). European Journal of Pharmacology 210: 115-120, 14 Jan 1992
16. Félétou M, Germain M, Thurieau C. Agonistic and antagonistic properties of the bradykinin β2 receptor antagonist, Hoe 140, in isolated blood vessels from different species. British Journal of Pharmacology 112: 683-689, Jun 1994
17. Sakamoto T, Sun J, Barnes PJ, et al. Effect of a bradykinin receptor antagonist, HOE 140, against bradykinin- and vagal stimulation-induced airway responses in the guinea-pig. European Journal of Pharmacology 251: 137-142, 14 Jan 1994
18. Sakamoto T, Elwood W, Barnes PJ. Evaluation of a bradykinin antagonist (HOE 140) against bradykinin and platelet activating factor induced airway responses in the guinea pig. Thorax 47: 241P, Mar 1992
19. Sakamoto T, Elwood W, Barnes PJ, et al. Effect of Hoe 140, a new bradykinin receptor antagonist, on bradykinin- and platelet-activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig. European Journal of Pharmacology 213: 367-373, 31 Mar 1992
20. Sakamoto T, Elwood W, Barnes PJ. Effect of a novel bradykinin antagonist (HOE140) against bradykinin, platelet activating factor, sodium metabisulfite and allergen induced airway responses in the guinea pig. American Review of Respiratory Disease 145: A859, Apr 1992
21. Wirth K, Hock FJ, Albus U. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. British Journal of Pharmacology 102: 774-777, Mar 1991
22. Damas J, Remacle-Volon G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. European Journal of Pharmacology 211: 81-86, 28 Jan 1992
23. Featherstone RL, Parry JE, Church MK. The effects of kinin antagonism with HOE 140 on the response of guinea-pigs to allergen. Clinical and Experimental Allergy 23 (Suppl. 1): 32, Feb 1993
24. Austin CE, Foreman JC, Scadding GK. Reduction by Hoe 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockage. British Journal of Pharmacology 111: 969-971, Apr 1994
25. Jerini AG. Jerini Announces Positive Phase II Study Results with Icatibant for the Treatment of Hereditary Angioedema. Media Release: 13 Jan 2004. Available from: URL: http://www.jerini.com
26. Avery J, Barber C. A topical bradykinin antagonist first clinical trial of icatibant nasal spray in seasonal allergic rhinitis. Allergy and Clinical Immunology News (Suppl. 2): 415, 1994